




1Q2026 Earnings Report

May 13, 2026

Investor Relations
ir@eyecenter.com.tw

Company Profile

Business Outlooks

1Q2026 Earnings Results


2026 Current Performance




<u>Ticker</u>	<u>Established</u>	<u>Listed</u>
3218TT	1994	2004
<u>Capital</u>	<u>Founders</u>	<u>Group Employees</u>
847M TWD	Dr. Pi-Jung Lin Dr. Shu-Fang Ou	600+ 1300+ (clinic included)

Taiwan's No.1 Eye Care Brand
One Stop Ophthalmology + Optometry Integration
The Vision Care Consolidator & Total Solution Provider

Three Target Generations & Core Businesses





As of Apr 2026

UVB's Core Competencies in the Industry

UVB Management (B2B)

Leading Technology & Procurement Capability

- Cutting edge medical technology & equipment
- Strong procurement and supply chain management

Professional Administrative Consulting & Support

- Experiences of sales, marketing, store expansion, HR, etc.
- Maximize efficiency and performance for stores

Proven Successful Franchise Business Model

- Leverage corporate capital to invest in high end medical equipment
- Duplicable business success attracts more doctors to join the brand

Retail Service (B2C)

Strong Medical & Optical Expertise

- Experts of practitioners, surgeons and opticians in the network
- Comprehensive clinical application services and training platform




Excellent Medical & Service Quality

- Assisted clinics to acquire JCI Accreditation 5 times since 2010
- One stop compound shop for professional vision care solutions



No.1 Vision Care Brand

- The dominator enjoying 50% of the refractive market share
- Reputable name and high customer satisfaction



Company Profile

 Business Outlook


1Q2026 Earnings Results

2026 Current Performance

High Myopia Prevalence Relating to Increasing Demands for Vision Improvement

- Long exposure to electronic devices has been causing early development of various eye diseases.
- In both Taiwan & China, over 80% of the teenagers suffers from myopia when they turn 18.
- Increasing demands under still low surgery penetration with the rise of technology and acceptance.

Myopia Prevalence in TW & CN, 2018



Source: Statistic Bureau, R.O.C. Taiwan, Morgan Stanley Research
National Health Commission of the People's Republic of China

Low Penetration of Refractive Surgery

	TW	CN
Population Eligible for Refractive Surgery	12M	700M
# of Refractive Surgery in 2022	38,000	2.4M
Penetration (annual)	0.32%	0.34%

Source: The Ophthalmologist, Internal Data

One-Stop Myopia Control Solutions



Orthokeratology



Daily Disposable
Soft Contact Lens



Defocus Incorporated
Multiple Segments
(DIMS) Lens



Atropine



Professional Service by UVB **e** 大學



Strong medical team
Prescriptions issued by doctors



Comprehensive outpatient consultation
Attentive follow-up management



Cutting-edge global technology
AI-driven precise fitting



Nationwide service locations
24-hour customer care hotline



Extensive optical experiences
Over 59,000 successful cases

Core Business & Driver for UVB's optometry in Taiwan



Pioneering Leadership through Revolutionary Equipment and All-Inclusive Surgical Solutions



SMILE = Small Incision Lenticule Extraction, proprietary technology of Zeiss



SMILE
10 Machines



SMILE PRO
12 Machines

SMILE[®]pro 2.0

Next-Gen Femtosecond
Laser Vision Correction

Safe, Minimally Invasive

0.2cm Incision, Rapid Recovery, No Dry Eyes

10-Second Speed

Fast & Secure

Advanced AI Navigation

Cyclotorsion & Centration Alignment,
Cloud-Based Big Data

SMILE Series Dominates Taiwan's Refractive Surgery Market



10''
秒

進化
清晰未來

精準再升級
AI導航
近視雷射

 STAAR SURGICAL™

EVO ICL = Implantable **Collamer®** Lens
(EVO = evolution)

- High biocompatibility with collagen protein
- Soft, flexible, and elastic
- UV protection

Ideal for Moderate to High Myopia

- Myopia: -3.00D to -20.00D
- Astigmatism: +1.00D to +4.00D
- Age: 21–60 years

30+ Years on the market

4+ Million ICL lenses
distributed worldwide

FDA approved in

EU, USA, Japan, Taiwan



Reversible and removable




Rapid surgery and recovery




0.3cm micro-incision



No cause of dry eyes





讓我們看看這個快速而簡單的ICL植入過程

EVO ICL vs. ARTIFLEX

Posterior Chamber



Anterior Chamber



Posterior Chamber

EVO ICL

Anterior Chamber

ARTIFLEX



Indications

Myopia: -3.00D to -20.00D
Astigmatism: +1.00D to +4.00D

Myopia: -8.00D to -14.50D
Astigmatism: +1.00D to +5.00D



Placement

Behind the iris & in front of the natural crystalline lens
(difficult to see)

In front of the iris
(visible)



Fixation

Natural anatomical fit: preserves corneal structure & biomechanics

Clips onto the surface of the iris: alters corneal architecture and biomechanics



Iridectomy

Not Required

May be Required




Clinical Cases

4 Million*

Fewer
(no official data)

Source: STAAR Surgical, 2024

1960:



Potential Targets for

Aged 55+

7.83M, 33%

Cataract/Presbyopia
Treatment

Aged 40-54

5.66M, 24%

Refractive/Presbyopia
Treatment

Aged 20-39

6.10M, 26%

Refractive/Myopia
Treatment

Based on population in 2023

Laser Vision Correction for Presbyopia


SMILE Series

- Minimally Invasive, 0.2 cm micro-incision
- Fast recovery, lower risk of dry eyes
- Ideal for patients needing quick visual recovery and with mild presbyopia symptoms

PRESBYOND® Laser Blended Vision (LBV)

- Customized treatment parameters
- Enhance stereoacuity, intermediate and overall vision quality
- Ideal for patients with significant presbyopia symptoms

PRESBYOND® Laser Blended Vision Technology



- ✓ Customized treatment profiles
- ✓ Optimize stereoacuity, eliminate multiple images
- ✓ All distances – near, intermediate to far
- ✓ Ideal for Reading & Digital Device Users



PRESBYOND® LBV 3+1 Machines

e 大學眼科

我做老花近視雷射
12年了

知名作家吳淡如
吳淡如

“遠、看近
都還是很方便”



Focus on World-Class Technology and
Top-Tier Offerings of Cataract Treatment



Ziemer - FEMTO LDV Z8



LenSx

- FLACS = Femtosecond Laser Assisted Cataract Surgery

31+1 Machines



High Precision & Safety
AI Customization
Fast Post-Surgery Recovery
Excellent Visual Quality

- IOL = Intraocular Lens



Full range of functional lenses tailored to individual needs
Monofocal, bifocal, multifocal, toric (astigmatism), myopia and
presbyopia correcting



Stable Growth of High-End
Elective Services in Taiwan



白內障手術
我選  **大學眼科**

微創精準 · 專業安全 · 恢復快

終於擺脫長久以來戴眼鏡的困擾。現在
不管是開車、看劇本、再小的字都看得
清清楚楚，讚啦！

台灣戲劇演員 

*王中憲醫師診所手術、沈曉鈞教授白內障雷射手術、陳明憲醫師白內障雷射手術、李國平醫師人工水晶體置換手術

2026 Store Expansion Plans

TAIWAN



Franchise Business :
Brand Licensing &
Clinical consulting services

33


● Existing Centers

- Space Enlargement
- Equipment Upgrades → **6 Renovations**
- Capacity Increase

● New Centers

- Mid & South Taiwan **+ 3~ Centers**
- Metropolitan Areas **(2 completed)**
- Network Extension

CHINA



Self-Operation : 4
Hospital Partnership : 5

9

● Existing Centers

- Space Expansion
- Equipment Upgrades
- Capacity & Service Increase

● New Centers

- Hospital Partnership **+ 1 Centers**
- Clinic Acquisition **(Q12027)**

2025-2026YTD Taiwan Store Expansions



**Launched in
Mar 2025**

**ARTS CENTER,
TAOYUAN**

**Launched in
Jul 2025**

**ZHUBEI,
HSINCHU**



**Launched in
Sep 2025**

**CHONGDE,
TAICHUNG**



**HENAN,
KEELUNG**

**Soft Opening
in Feb 2026**



**DOULIU,
YUNLIN**

**Launched in
Mar 2026**




PENGHU Universal Optical

**Upgraded in
May 2026**



★ **Newly Added Centers**



Brand New Yunlin Douliu Eye Center



Douliu Universal Eye Center – Launched in March 2026



- The first partnered clinic in Yulin, located within the Douliu Taiping Street commercial district.
- Approximately 1,160 m² across 4 floors, including two operating rooms.
- Equipped with SMILE refractive surgery and femtosecond laser cataract systems, together with a brand-new optical retail center.



Brand New Keelung Henan Eye Center

Henan Universal Eye Center – Soft Opening in February 2026

- The first partnered clinic in Keelung, located in the city center with a medical clinic cluster; close to the Keelung Port commercial district and night market area.
- Approximately 330 m² of space on one floor, including two operating rooms.
- SMILE and femtosecond cataract platforms, with a new optical retail center to be introduced.



- Healthcare liberalization pilot city
- Approval for foreign-invested hospitals
- Introduction of international-standard healthcare

Government Support

- Suzhou North High-Speed Rail Station – integrated transport and commercial complex
- Rapid connectivity across the Yangtze River Delta
- Emerging Xiangcheng District

Transport Hub

Policy Incentives

- Rent exemptions
- ~3,200m² planned facility
- Lower development and operating costs

Strategic Positioning

- First private foreign-invested tertiary ophthalmology specialty hospital in the country
- Strong government partnerships supporting market expansion



Groundbreaking ceremony for Universal Eye Hospital. Jan 12, 2026

- Expansion completion targeted in 2027
- Hangzhou and Ningbo reachable within 50 minutes





Company Profile

UVB Business Outlooks


1Q2026 Earnings Results

2026 Current Performance



1Q2026 Consolidated Statements of Income

Items in Thousand TWD	1Q2026	%	4Q2025	%	QoQ	1Q2025	%	YoY
Operating Revenue	1,089,806	100	1,033,183	100	5.5%	1,123,220	100	-3.0%
Operating Costs	464,479	42.6	426,007	41.2		456,612	40.7	
Gross Profit	625,327	57.4	607,176	58.8	-1.4ppt	666,608	59.3	-1.9ppt
Operating Expenses	291,473	26.7	269,009	26.0	+0.7ppt	273,948	24.4	+2.3ppt
Operating Profit	333,854	30.6	338,167	32.7	-1.3%	392,660	35.0	-15.0%
Non-operating Income & Expenses	21,044	1.9	15,791	1.5		58,115	5.2	
Profit Before Income Tax	354,898	32.6	353,958	34.3		450,775	40.1	
Income Tax	66,969	6.1	61,942	6.0		80,606	7.2	
Net Profit	287,929	26.4	292,016	28.3		370,169	33.0	
Net Profit Attributable to Owners of the Parent	280,773	25.8	294,276	28.5	-4.6%	362,648	32.3	-22.6%
Non-Controlling Interest	7,156	0.7	(2,260)	(0.2)		7,521	0.7	
EPS (NT\$)	3.31		3.48			4.28		



Sales Breakdown by Business



Ophthalmology	2025	1Q2026
Technical Service	50%	49%
Medical Supplies	15%	18%
Consulting	4%	4%
Store Rent	5%	5%




■ China
■ Taiwan
In million TWD




Revenue, Profit & EPS

In million TWD



Margin Ratios



	YEAR	2020	2021	2022	2023	2024	2025	2026
Consolidated	ROE	25.9%	28.0%	33.7%	34.5%	29.6%	26.7%	29.0%
	ROA	17.0%	18.0%	21.3%	22.4%	19.6%	18.1%	18.6%
Parent (Standalone)	ROE	27.6%	29.0%	35.1%	35.8%	31.3%	27.3%	29.3%
	ROA	18.9%	19.4%	22.9%	23.8%	21.3%	19.0%	19.1%

- ROE figures are annualized based on average equity attributable to shareholders of the parent company.
- ROA figures are annualized based on average total asset.

YEAR	2021	%	2022	%	2023	%	2024	%	2025	%
EPS	7.82	100%	10.64	100%	12.34	100%	12.57	100%	12.31	100%
Dividend	5.5	70%	6.6	62%	7	57%	7.5	60%	7.75	63%
- Cash	5	64%	6	56%	7	57%	7.5	60%	7.75	63%
- Stock	0.5	6%	0.6	6%	0	0%	0	0%	0	0%
Capital	761M		799M		847M		847M		847M	



Company Profile

UVB Business Outlooks


1Q2026 Earnings Results

2026 Current Performance


Steady Growth Momentum

In Million TWD

Monthly Sales



2026 Revenue	2025 Revenue	YoY%
1,470	1,478	-0.5%



Thank You

Investor Relations
ir@eyecenter.com.tw

 Universal Vision Biotechnology